Sadrizadeh Ali, Bagheri Reza, Soltani Ehsan, Anvari Kazem, Toussi Mehdi Seilanian, Moadikhah Soheila
Cardiothoracic Surgery & Transplant Research Center, Emam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of General Surgery, Acute Care Surgery Research Center, Mashhad University of Medical Sciences, Taleghani University Hospital, Mashhad, Iran.
J Gastrointest Cancer. 2018 Mar;49(1):50-56. doi: 10.1007/s12029-016-9899-0.
Esophageal cancer is the eighth most common type of cancer worldwide. For the treatment of which, surgical intervention alone or with neoadjuvant chemoradiotherapy or chemotherapy is recommended. In this study, we aimed to compare the benefits of neoadjuvant chemoradiotherapy versus postoperative chemoradiotherapy.
We collected data regarding 325 patients admitted for esophageal cancer to Qaem Hospital, Mashhad, Iran, during 2006-2016. The participants were divided into two groups of neoadjuvant and postoperative adjuvant therapies. Chi-square, McNemar, Kaplan-Mayer, and multivariate regression tests were performed using SPSS.
Gender, age, stage of the disease, tumor grade and location, disease histopathology, and the recurrence showed no significant differences between the two groups (P ˃ 0.05), but there was a significant association between the two types of treatment in terms of postoperative complications (P = 0.03). We followed up 147 patients postoperatively and found no significant differences between the groups (P ˃ 0.05).
No conclusion can be drawn on whether there are any advantages in adjuvant chemoradiotherapy over neoadjuvant approaches. Further confirmatory trials, particularly randomized trials, are necessary before any recommendations can be made.
食管癌是全球第八大常见癌症类型。对于其治疗，推荐单独手术干预或联合新辅助放化疗或化疗。在本研究中，我们旨在比较新辅助放化疗与术后放化疗的益处。
我们收集了2006年至2016年期间伊朗马什哈德卡姆医院收治的325例食管癌患者的数据。参与者被分为新辅助治疗组和术后辅助治疗组。使用SPSS进行卡方检验、 McNemar检验、 Kaplan - Mayer检验和多因素回归分析。
两组在性别、年龄、疾病分期、肿瘤分级和位置、疾病组织病理学及复发方面无显著差异（P＞0.05），但在术后并发症方面，两种治疗类型之间存在显著关联（P = 0.03）。我们对147例患者进行了术后随访，发现两组之间无显著差异（P＞0.05）。
关于辅助放化疗相对于新辅助治疗方法是否具有任何优势，无法得出结论。在做出任何推荐之前，需要进一步的验证性试验，尤其是随机试验。
